Učitavanje...
Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors
Since its approval by the US Food and Drug Administration in February 2002, the tyrosine kinase inhibitor, imatinib, has become the standard of care for patients with metastatic or unresectable KIT-positive gastrointestinal stromal tumors (GISTs). Imatinib functions by blocking the adenosine triphos...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2012
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3424497/ https://ncbi.nlm.nih.gov/pubmed/22942908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834012450935 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|